PBC

Momcozy’s Award-Winning Nursing Bras Takes the Spotlight in 2024

Retrieved on: 
Vendredi, avril 26, 2024
Pregnancy, Woman, Classic, Choice, Gold, Nursing, Web Cartoonists' Choice Awards, PBC

Its revolutionary Classic - Jelly Strip Support Nursing Bra YN46 has taken the spotlight in 2024.

Key Points: 
  • Its revolutionary Classic - Jelly Strip Support Nursing Bra YN46 has taken the spotlight in 2024.
  • The seamless nursing bra has won three prestigious awards in 2024: Mom's Choice Awards 2024 , PBC Awards 2024—Best Nursing Bra , and Bizziebaby Awards 2024—Gold .
  • The YN46 seamless nursing bra also scooped gold in Bizziebaby’s Awards 2024 in the breastfeeding and pregnancy lingerie categories.
  • Furthermore, the Classic - Ultra Soft Nursing Bra YN21 is a testament to excellence, having claimed victories at both the Made for Mums Awards 2024 and the Bizziebaby Awards 2024.

The Vita Coco Company Announces the Formation of The Vita Coco Community Foundation

Retrieved on: 
Mardi, avril 23, 2024
B Lab, Seedling, Certification, Sustainability, B Corporation (certification), Hunger, COCO, Environment, Tree, Tran, PBC, Drink, Knowledge, Bank

NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leader in the functional beverage space with a portfolio of better-for-you brands, announced today that it has formed a 501(c)(3) nonprofit, The Vita Coco Community Foundation (“Foundation”), with a mission of empowering communities to build an enduring, resilient society to thrive for future generations.

Key Points: 
  • NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ: COCO) (“Vita Coco” or the “Company”), a leader in the functional beverage space with a portfolio of better-for-you brands, announced today that it has formed a 501(c)(3) nonprofit, The Vita Coco Community Foundation (“Foundation”), with a mission of empowering communities to build an enduring, resilient society to thrive for future generations.
  • Those areas include:
    The Vita Coco Community Foundation plans to foster the pursuit of knowledge, upward mobility and livelihoods.
  • The formation of the Vita Coco Community Foundation is the latest step the Company has taken to reinvest in the communities in which the Company and its partners operate.
  • To learn more about the Vita Coco Community Foundation, visit https://vitacoco.com/pages/foundation
    You can also connect with Vita Coco at vitacoco.com, Twitter, Instagram and TikTok.

Zevia to Participate in Upcoming Investor Conferences

Retrieved on: 
Mercredi, mai 1, 2024
Retail, General Health, Health, Food, Beverage, PBC, Conference

Zevia PBC (“Zevia” or the “Company”) (NYSE: ZVIA), the company bringing great tasting, zero sugar beverages made with simple, plant-based ingredients across all usage occasions to households across income levels, today announced that its President and Chief Executive Officer, Amy Taylor and Chief Financial Officer, Girish Satya will participate in two upcoming investor conferences.

Key Points: 
  • Zevia PBC (“Zevia” or the “Company”) (NYSE: ZVIA), the company bringing great tasting, zero sugar beverages made with simple, plant-based ingredients across all usage occasions to households across income levels, today announced that its President and Chief Executive Officer, Amy Taylor and Chief Financial Officer, Girish Satya will participate in two upcoming investor conferences.
  • At the Goldman Sachs Global Staples Forum, Ms. Taylor and Mr. Satya will meet with investors and present at approximately 1:10 p.m. Eastern Time on Tuesday, May 14, 2024.
  • Live webcasts of their presentations will be available on the Investor Relations section of Zevia’s website at https://investors.zevia.com/ during the event.
  • Shortly following both events, a replay will be available at https://investors.zevia.com/ for approximately thirty (30) days.

Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting

Retrieved on: 
Lundi, avril 29, 2024
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, PFS, Brentuximab vedotin, Triple-negative breast cancer, Lung cancer, MBC, ASCO, Lymphoma, PFE, Metastasis, ALK, Breast cancer, Learning, CRS, Food, Colorectal cancer, Abstract, RRMM, Rituximab, ADC, HR, CDK4, De novo, Spacecraft, DLBCL, Tucatinib, Anaplastic lymphoma kinase, Safety, Crizotinib, Pembrolizumab, Survival, EZH2, Pros, Inc., Neoplasm, Progression-free survival, Recurrence, PAL, Biologics license application, HRR, Hodgkin lymphoma, Patient, Society, Cyclin-dependent kinase 4, Cytokine release syndrome, Annual general meeting, APLS, PBC, Lenalidomide, B-cell lymphoma, Pharmaceutical industry

Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago.
  • “We are excited to participate in our first ASCO Annual Meeting following the creation of Pfizer’s new Oncology organization, where we will highlight our efforts to accelerate breakthrough medicines that help people with cancer live better and longer lives,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.
  • An oral presentation on extended duration of response from the Phase 3 MOUNTAINEER trial adds to the positive profile of TUKYSA in colorectal cancer.
  • Those interested in learning more can visit www.Pfizer.com/apls to access the summaries starting Friday, May 24.

Global Generative AI Market Research, 2023-2024 & 2033: Start-ups Accounted for Just 12% Market Share in 2022 but More Companies are Expected to Enter the $230+ Billion Market Every Year - ResearchAndMarkets.com

Retrieved on: 
Lundi, avril 29, 2024
Technology, Start-Up, Professional Services, Artificial Intelligence, USD, Investment, Learning, Social media, Safety, NLP, Traction, Partnership, Business process, Research, Natural language processing, Growth, Intelligence, Amazon, Automation, Synthetic media, Artificial Intelligence Act, Benchmarking, GPT, Marketing, Health, Creativity, Generative, Advertising, Student, Annapurna Labs, Risk assessment, PBC, AWS, Algorithm, Deep learning, Medical device

In 2022, the generative AI market was dominated by established players, accounting for 88% of the market share, whereas start-ups managed to capture 12% of the market.

Key Points: 
  • In 2022, the generative AI market was dominated by established players, accounting for 88% of the market share, whereas start-ups managed to capture 12% of the market.
  • With the increasing adoption of generative AI solutions across various industries, more players will enter the global generative AI market with each passing year.
  • The natural language processing (NLP) segment dominated the global generative AI market (by offering) in 2022 with a 38.89% share.
  • Competitive Strategy: Key players in the generative AI market analyzed and profiled in the study involve major companies offering generative AI solutions designed for various applications.

United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024

Retrieved on: 
Mercredi, avril 24, 2024
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, United Therapeutics, Webcast, Creativity, UTHR, PBC, Therapy, Patient

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.
  • A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
  • United Therapeutics will host a public webcast Wednesday, May 1, 2024, at 9:00 a.m. Eastern Time.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

Joe Hand Promotions Launches New Business: OnTap Sports

Retrieved on: 
Mercredi, avril 24, 2024
General Sports, Sports, Restaurant, Bar, Marketing, Communications, Events, Concerts, Retail, Entertainment, WWE, Sport, Boxing, UFC, ONTAP, Love, PBC, AEW, Business, DAZN

Joe Hand Promotions , the global leader in live sports viewing for the hospitality market which includes bars, restaurants, and casinos, is proud to announce the launch of its latest business, OnTap Sports .

Key Points: 
  • Joe Hand Promotions , the global leader in live sports viewing for the hospitality market which includes bars, restaurants, and casinos, is proud to announce the launch of its latest business, OnTap Sports .
  • Joe Hand Promotions has partnered with the world's most used sports bar finder, FANZO , to create the ultimate barfinder in the United States, OnTap Sports , which offers customers an enhanced platform to discover live sports events showing at local establishments.
  • In addition, Joe Hand Promotions’ customers can become a paid sponsored establishment to give their location premium placement on the OnTap Sports barfinder.
  • From our roots in selling content to bars, we've always hoped to provide a resource for all fans, ensuring they know exactly where to go to find their favorite events,” said Joe Hand, Jr., President of Joe Hand Promotions.

United Therapeutics Announces World’s First Successful Xenothymokidney Transplant

Retrieved on: 
Vendredi, avril 26, 2024
Cardiology, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Research, Surgery, Science, Clinical Trials, University, Birmingham School of Law, Cell, Transplant, Food, Tissue, Human services, Heart, NYU Langone Health, Surgeon, History, Doctor of Philosophy, UTHR, Patient, Regenerative medicine, Multimedia, Creativity, Immune system, PBC, Therapy, Food and Drug Administration, Knowledge

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.
  • (Photo: Business Wire)
    - The first-ever transplant of a xenothymokidney into a living human recipient;
    - The first-ever combined mechanical heart pump and organ transplant; and
    The transplant is the third xenotransplant using United Therapeutics’ xeno organs, following two successful UHeart™ transplants at the University of Maryland Medicine in 2022 and 2023.
  • United Therapeutics’ xenothymokidney, known by the proposed trade name UThymoKidney, is an investigational-stage xenokidney from a pig with a single genetic edit, together with tissue from the same pig’s thymus.
  • United Therapeutics is preparing for clinical trials of its xenokidney, xenothymokidney, and xenoheart products, following completion of ongoing preclinical studies required by the FDA.

Zevia to Announce First Quarter 2024 Results on Wednesday, May 8, 2024

Retrieved on: 
Mercredi, avril 24, 2024
Online Retail, Retail, Health, Fitness & Nutrition, Supermarket, Food, Beverage, PBC

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the first quarter ended March 31, 2024 before the market open on Wednesday, May 8, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Key Points: 

Zevia PBC (“Zevia”) (NYSE:ZVIA) today announced that it will release its financial results for the first quarter ended March 31, 2024 before the market open on Wednesday, May 8, 2024 followed by a conference call at 8:30 a.m. Eastern Time to discuss the results.

Mark Cuban Cost Plus Drug Company and Vivid Clear Rx Team Up to Increase Access to Low-Priced Prescriptions

Retrieved on: 
Lundi, avril 22, 2024
Professional Services, Health, Insurance, Human Resources, General Health, Pharmaceutical, Public, Pharmacy, Cost Plus Drugs, World Market (store), Prescription, Patient, Multimedia, PBC

The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.

Key Points: 
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) and Vivid Clear Rx, a pass-through pharmacy benefit manager, have teamed up to make it easy for patients to access low-cost prescriptions.
  • View the full release here: https://www.businesswire.com/news/home/20240422460983/en/
    Now, eligible Vivid Clear Rx members have direct access to purchase affordable prescriptions and have them shipped through Cost Plus Drugs using their pharmacy benefit plan.
  • By collaborating together, Cost Plus Drugs and Vivid Clear Rx aim to control drug costs for health plans and patients nationwide.
  • The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates.